Global Blood Therapeutics, Inc. (NASDAQ:GBT – Get Rating) – Research analysts at Cantor Fitzgerald issued their FY2022 earnings estimates for shares of Global Blood Therapeutics in a research note issued to investors on Wednesday, September 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings per share of ($4.55) for the year. Cantor Fitzgerald has a "Neutral" rating on the stock. The consensus estimate for Global Blood Therapeutics' current full-year earnings is ($4.71) per share. Cantor Fitzgerald also issued estimates for Global Blood Therapeutics' FY2023 earnings at ($3.03) EPS.

Get Global Blood Therapeutics alerts:

GBT has been the subject of several other research reports. Cowen lowered shares of Global Blood Therapeutics to a "market perform" rating and boosted their price target for the company from $67.00 to $68.50 in a report on Tuesday, August 9th. Guggenheim boosted their price target on shares of Global Blood Therapeutics to $72.00 in a report on Monday, August 15th. Canaccord Genuity Group upgraded shares of Global Blood Therapeutics from a "hold" rating to a "buy" rating and boosted their price target for the company from $40.00 to $72.00 in a report on Monday, August 8th. Oppenheimer lowered shares of Global Blood Therapeutics to a "market perform" rating in a report on Monday, August 15th. Finally, Wedbush downgraded shares of Global Blood Therapeutics to a "neutral" rating in a research report on Monday, August 15th. Twelve research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $65.50.

Global Blood Therapeutics Trading Up 0.0 %

NASDAQ:GBT opened at $67.99 on Friday. Global Blood Therapeutics has a one year low of $21.65 and a one year high of $73.02. The company has a debt-to-equity ratio of 4.92, a quick ratio of 6.17 and a current ratio of 6.88. The firm has a market cap of $4.59 billion, a P/E ratio of -13.57 and a beta of 0.46. The firm has a 50-day simple moving average of $58.27 and a 200-day simple moving average of $40.00.

Global Blood Therapeutics (NASDAQ:GBT – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.07). Global Blood Therapeutics had a negative net margin of 137.30% and a negative return on equity of 170.37%. The company had revenue of $71.55 million for the quarter, compared to the consensus estimate of $64.39 million. During the same quarter in the previous year, the business earned ($1.12) EPS.

Insiders Place Their Bets

In other Global Blood Therapeutics news, insider Nazila Habibizad sold 4,678 shares of the business's stock in a transaction that occurred on Thursday, August 18th. The shares were sold at an average price of $67.19, for a total transaction of $314,314.82. Following the sale, the insider now owns 8,918 shares of the company's stock, valued at approximately $599,200.42. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.90% of the stock is owned by insiders.

Institutional Trading of Global Blood Therapeutics

Large investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC boosted its holdings in shares of Global Blood Therapeutics by 75.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the company's stock valued at $52,000 after acquiring an additional 650 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in shares of Global Blood Therapeutics in the 1st quarter valued at $448,000. Candriam Luxembourg S.C.A. lifted its stake in shares of Global Blood Therapeutics by 16.7% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 756,708 shares of the company's stock valued at $26,211,000 after purchasing an additional 108,369 shares during the period. Fairmount Funds Management LLC lifted its stake in shares of Global Blood Therapeutics by 59.1% in the 1st quarter. Fairmount Funds Management LLC now owns 1,182,307 shares of the company's stock valued at $40,955,000 after purchasing an additional 439,307 shares during the period. Finally, Vestmark Advisory Solutions Inc. lifted its stake in shares of Global Blood Therapeutics by 44.3% in the 1st quarter. Vestmark Advisory Solutions Inc. now owns 12,669 shares of the company's stock valued at $439,000 after purchasing an additional 3,892 shares during the period.

Global Blood Therapeutics Company Profile

(Get Rating)

Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.

Featured Stories

• Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
• MarketBeat: Week in Review 9/19 – 9/23
• Why Does Tesla Stock Remain Resilient?
• 2 Semiconductor Stocks To Watch For Reversals
• Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
• Will Crowdstrike Get A Boost From Increased EPS Guidance?

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.